May 23 (Reuters) - Verastem Inc :
* VERASTEM ONCOLOGY ANNOUNCES POSITIVE INITIAL INTERIM SAFETY AND EFFICACY RESULTS FROM RAMP 205 TRIAL EVALUATING AVUTOMETINIB PLUS DEFACTINIB IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN FIRST-LINE METASTATIC PANCREATIC CANCER
* VERASTEM INC: 83% (5/6) OF PATIENTS ACHIEVED A CONFIRMED PARTIAL RESPONSE IN COHORT 1, MOST MATURE DOSE LEVEL
* VERASTEM INC: ONE DOSE-LIMITING TOXICITY WAS OBSERVED IN STUDY
* VERASTEM INC: FOLLOW UP OF PATIENTS IN ADDITIONAL DOSE AND SCHEDULE COHORTS IS ONGOING TO DETERMINE RECOMMENDED PHASE 2 DOSE FOR STUDY EXPANSION
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Comments